Verona Pharma VRNA 2022 Respiratory Disease Therapies Presentation

Verona Pharma presents ensifentrine, a Phase 3 first-in-class inhaled dual PDE3/PDE4 inhibitor for COPD maintenance treatment, targeting a $10B market with over 1M symptomatic patients on dual/triple therapy. The candidate demonstrated positive Phase 3 data on lung function and exacerbations with a safety profile consistent with placebo.